GeoPharma Issues Expanded Corporate Profile

LARGO, Fla., Jan. 22 /PRNewswire-FirstCall/ -- In an effort to continue to
communicate precisely who we are and what we do, GeoPharma, Inc.
(Nasdaq: GORX) has decided to issue this expanded corporate profile to reflect
its recent acquisition and other new additions to its business model.
Company Profile:
GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified
business model participating in 3 main market segments: Specialty Pharma,
Manufacturing, and Distribution. The Specialty Pharma division specializes in
the formulation of generic drugs for human and veterinary usage and the
development of medical devices used by oncologists and other medical
professionals. The Manufacturing and Distribution divisions, manufacture,
package, and distribute generic drugs, nutraceuticals, cosmetics, and
functional food products for companies worldwide.
The Specialty Pharma segment is composed of GeoPharma subsidiaries,
Belcher Pharmaceuticals, Inc. and American Antibiotics, Inc. Belcher is a
state-of-the-art 50,000 Sq. Ft. FDA-registered manufacturing, research and
development facility designed to produce generic drugs and Cephalosporins.
American Antibiotics is a Beta-Lactam facility dedicated to Amoxicillin,
Ampicillin, and Penicillin production. American Antibiotics operates out of
100,000 Square Feet in Baltimore, Maryland. GeoPharma recently received FDA
approval to manufacture Carprofen, a generic veterinary drug used to treat
arthritis in dogs. GeoPharma also announced it has acquired the rights to a
diagnostic technology for early stage detection of ovarian cancer.
Additionally, GeoPharma's drug pipeline contains 12 ANDA's and other drug
products, several of these initiatives are pending approval and process
completion.
The Manufacturing segment is highlighted by GeoPharma's other subsidiaries
Libi Labs, Inc., Innovative Health Products, Inc. and EZ-Med Technologies,
Inc. Libi Labs primary focus is cosmeceuticals, while Innovative Health
Products handles the bulk of GeoPharma's contract manufacturing business. EZ-
Med Technologies uses its own patented soft-chew technology to manufacture
companion animal nutritional supplements.
The Distribution segment showcases the GeoPharma subsidiaries Breakthrough
Engineered Nutrition, Inc. and Bob O'Leary Health Food Distributor Co., Inc.
(BOSS). Breakthrough develops markets and distributes GeoPharma's own branded
dietary supplements. BOSS, is a full line leading distributor of Sports
Nutrition products, Dietary Supplements, and Performance Beverages. BOSS
distributes products manufactured by over 100 vendors, including top health
food and nutrition brands such as Iovate, EAS, VPX, BSN, and Cytosport. Both
Breakthrough and Boss products are distributed nationwide and internationally
in specialty stores and mass outlets, including Target, Wal-Mart, GNC,
Walgreens, CVS, Rite Aid, Duane Reade and many others.
GeoPharma's growth strategy is to capitalize on its research and
manufacturing expertise to develop medical devices and high margin generic
drug products for niche markets with high barriers to entry. GeoPharma's
competitive advantage in these areas is in its ability to navigate the
challenges that such market pursuits present effectively.
Currently GeoPharma employs nearly 300 people and operates facilities in
Florida, Maryland, Pennsylvania, Nevada, Rhode Island, and Texas utilizing
over 330,000 Sq Ft. of office, warehouse, manufacturing and laboratory
facilities.
For further information visit the "For Investors" section of the GeoPharma
website at www.geopharmainc.com
Safe Harbor Statement: This press release may contain statements, which
constitute forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including those regarding the
company and its subsidiaries' expectations, intentions, strategies and beliefs
pertaining to future performance. All statements contained herein are based
upon information available to the company's management as of the date hereof,
and actual results may vary based upon future events, both within and without
management's control. Important factors that could cause such differences are
described in the company's periodic filings with the Securities and Exchange
Commission.
Contact Information:
Alexander Nachman
Director of Investor and Media Relations
GeoPharma, Inc
727-471-0850 x243
Email:
IR@GeoPharmainc.com

SOURCE GeoPharma, Inc.

Alexander Nachman, Director of Investor and Media Relations of GeoPharma, Inc,
+1-727-471-0850 x243, IR@GeoPharmainc.com